In 2009, a landmark trial described a “Lazarus” response in NSCLC patients with a PS of 34—a dramatic improvement in PS was found in 70% of patients who harbored an EGFR mutation [9,10]. Here, EGFR is linked to non-small cell lung carcinoma.